Autres langues Iconovo AB

Actions

ICO

SE0010868943

Marché Fermé - Nasdaq Stockholm Autres places de cotation 17:10:10 10/05/2024			Varia. 5j.	Varia. 1 janv.
7,84 ^SEK	-1,51%		-2,00%	-32,12%

06/05	Le suédois Iconovo va recevoir un brevet chinois pour l'inhalateur ICOres	MT
06/05	Iconovo AB (publ) reçoit la protection d'un brevet pour Icores en Chine	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Sweden's Iconovo to Receive Chinese Patent for ICOres Inhaler	06/05
Iconovo receives patent protection for ICOres® in China	06/05
Iconovo AB Receives Patent Protection for Icores in China	06/05
Iconovo Q1 - Solid quarter with a near-term catalyst on the horizon	26/04
Iconovo AB Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04
Iconovo to present positive data from a feasibility study on Nanofitins® in ICOone®	11/03
Iconovo AB and Affilogic to Present Positive Data from a Feasibility Study on Nanofitins in ICOone	11/03
Iconovo receives grant of SEK 680,000 from Innowwide for market efforts in South Korea	05/03
Iconovo Q4 - Aligned with our expectations and a directed issue announcement	19/02
Iconovo AB Reports Earnings Results for the Full Year Ended December 31, 2023	15/02
Iconovo AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/02
Iconovo carries out a directed share issue of SEK 33.3 million, partly subject to subsequent approval by the Extraordinary General Meeting, and brings forward the publication of the year-end report	15/02
Iconovo signs additional contract with Kiox Pharma for the development of a new inhalable treatment for interstitial lung disease	07/02
Iconovo AB Signs Additional Contract with Kiox Pharma for the Development of A New Inhalable Treatment for Interstitial Lung Disease	07/02
Iconovo launches improved versions of nasal ICOone® inhalers	06/02
Iconovo AB Launches Improved Versions of Nasal ICOone Inhalers	06/02
Iconovo receives order from Top-10 Pharma company for evaluation of multi-dose inhaler	01/02
Iconovo Receives Order from Top-10 Pharma Company for Evaluation of Multi-Dose Inhaler	01/02
Iconovo recruits Gary Pitcairn (PhD) as Senior Scientific Advisor	08/01
Redeye Initiates Coverage of Iconovo	06/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Iconovo AB

Actions

ICO

SE0010868943

Autres langues

Filtres